CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company
Replimune Group, Inc.
Sign in to watch- Ticker
- REPL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 822082553
- Phone
- (781) 222-9600
- Business address
- 500 UNICORN PARK, WOBURN, MA, 01801
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $654,036
- in 3 filings
Net −$654,036. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-01 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy)uy) | +44,500 | 44,500 | ||
| 2026-04-01 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Option (right to buy)uy) | +44,500 | 44,500 | ||
| 2026-04-01 | Sarchi Christopher Chief Commercial Officer | Grant or award | +50,000 | 201,588 | ||
| 2026-04-01 | Sarchi Christopher Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2026-04-01 | Astley-Sparke Philip Director | Grant or award | +50,000 | 1,430,071 | ||
| 2026-04-01 | Astley-Sparke Philip Director | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2026-04-01 | Oliger Christy J. Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | Xynos Konstantinos Chief Medical Officer | Grant or award | +50,000 | 249,685 | ||
| 2026-04-01 | Xynos Konstantinos Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2026-04-01 | Balachandran Madhavan Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | Schwendenman Andrew Chief Accounting Officer | Grant or award | −36,667 | 114,951 | ||
| 2026-04-01 | Schwendenman Andrew Chief Accounting Officer | Grant or award · Employee Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2026-04-01 | Patel Sushil Chief Executive Officer | Grant or award | +251,240 | 784,816 | ||
| 2026-04-01 | Patel Sushil Chief Executive Officer | Grant or award · Employee Stock Option (right to buy) | +376,860 | 376,860 | ||
| 2026-04-01 | Dhingra Kapil Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | Pucci Paolo Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | SLATTERY JOSEPH P Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | Peeples-Dyer Veleka Director | Grant or award · Stock Option (right to buy) | +44,500 | 44,500 | ||
| 2026-04-01 | Hill Emily Luisa Chief Financial Officer | Grant or award | +50,000 | 244,368 | ||
| 2026-04-01 | Hill Emily Luisa Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 |
Page 2 of 8 · 143 trades